^
Association details:
| Biomarker: | ALK I1171N |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA
Excerpt:
We report the case of a patient with ALK-rearranged NSCLC who presented acquired resistance to crizotinib and then alectinib. Sequencing analyses of DNA from a liver metastasis biopsy sample and circulating tumor DNA both found the same I1171N ALK kinase domain mutation, known to confer resistance to certain ALK inhibitors. However, the patient then received ceritinib, a 2nd generation ALK inhibitor, and achieved another partial response.
DOI:
10.1016/j.lungcan.2016.06.010
